Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Kevin Heller, MD
Advertisement
Executive Vice President, Research and Development, Jasper Therapeutics
Articles by Kevin Heller, MD
The executive vice president of research and development at Jasper Therapeutics discussed positive data from trials of JSP191 in MDS and AML.
The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.
Advertisement
Latest Updated Articles
Improving Gene and Cell Therapy Conditioning Regimens With JSP191Published: August 1st 2021 | Updated:
- Investigating JSP191 for More Tolerable Gene and Cell Therapy Conditioning
Published: August 4th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
CGTLive®’s Weekly Rewind – October 24, 2025
2
Guess the Therapy Answer October 23, 2025
3
Quarter Century Update: What Were the Most Significant Inflection Points or Breakthroughs in the Field?
4
